Epidemiological and statistical considerations for interpreting and communicating oncology clinical trials

被引：3
|
作者：
Heller, Jane [1 ]
机构：
[1] Charles Sturt Univ, Sch Anim & Vet Sci, Wagga Wagga, NSW 2650, Australia
来源：
VETERINARY JOURNAL | 2015年 / 205卷 / 02期
关键词：
Oncology; Epidemiology; Randomised controlled trial; Statistics; Risk; Veterinary; RANDOMIZED CONTROLLED-TRIALS; RELATIVE RISK; STATEMENT; INFORMATION; GUIDELINES; QUALITY; ABSENCE; CANCER;
D O I：
10.1016/j.tvjl.2015.02.014
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
The use of randomised controlled trials (RCTs) in veterinary oncological research and practice is increasing as is the number of relevant scientific publications. While clear guidelines exist for the reporting of RCTs, a thorough understanding of statistical and epidemiological concepts is required in order to accurately interpret and then impart the results of such trials, and to make balanced decisions regarding the uptake of published findings. This review presents the most important epidemiological and statistical considerations that are needed in order to interpret and communicate with confidence the results of oncology clinical trials. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码：233 / 237
页数：5
相关论文
共 50 条
  • [1] Oncology Nursing Considerations in a Clinical Trials Environment
    Legor, Kristen
    SEMINARS IN ONCOLOGY NURSING, 2020, 36 (03)
  • [2] Clinical outcome assessment trends in clinical trials-Contrasting oncology and non-oncology trials
    Kim, Yeonju
    Gilbert, Mark R.
    Armstrong, Terri S.
    Celiku, Orieta
    CANCER MEDICINE, 2023, 12 (16): : 16945 - 16957
  • [3] Regulatory considerations on the enrollment of older adults in oncology clinical trials
    Raimi-Abraham, Bahijja Tolulope
    de Orbe Izquierdo, Maria Silvia
    Collignon, Olivier
    Cerreta, Frahcesca
    JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (03) : 151 - 153
  • [4] Methodological quality of oncology noninferiority clinical trials
    Wayant, Cole
    Ross, Andrew
    Vassar, Matt
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [5] Quality improvements in radiation oncology clinical trials
    Smith, Koren
    Ulin, Kenneth
    Knopp, Michael
    Kry, Stephan
    Xiao, Ying
    Rosen, Mark
    Michalski, Jeff
    Iandoli, Matthew
    Laurie, Fran
    Quigley, Jean
    Reifler, Heather
    Santiago, Juan
    Briggs, Kathleen
    Kirby, Shawn
    Schmitter, Kate
    Prior, Fred
    Saltz, Joel
    Sharma, Ashish
    Bishop-Jodoin, Maryann
    Moni, Janaki
    Cicchetti, M. Giulia
    FitzGerald, Thomas J.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Novel dose-finding designs and considerations on practical implementations in oncology clinical trials
    Huang, Bo
    Bycott, Paul
    Talukder, Enayet
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (01) : 44 - 55
  • [7] Endpoints in oncology clinical trials
    Kilickap, Saadettin
    Demirci, Umut
    Karadurmus, Nuri
    Dogan, Mutlu
    Akinci, Bulent
    Sendur, Mehmet Ali Nahit
    JOURNAL OF BUON, 2018, 23 : S1 - S6
  • [8] Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia
    Habr, Dany
    Singh, Manmohan
    Uehara, Roberto
    ONCOLOGY AND THERAPY, 2024, 12 (01) : 115 - 129
  • [9] Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials
    Alosh, Mohamed
    Huque, Mohammad F.
    Bretz, Frank
    D'Agostino, Ralph B., Sr.
    STATISTICS IN MEDICINE, 2017, 36 (08) : 1334 - 1360
  • [10] Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
    Ratitch B.
    Rodriguez-Chavez I.R.
    Dabral A.
    Fontanari A.
    Vega J.
    Onorati F.
    Vandendriessche B.
    Morton S.
    Damestani Y.
    Digital Biomarkers, 2022, 6 (03) : 83 - 97
12345